BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15367415)

  • 1. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas.
    Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS
    Ann Oncol; 2004 Oct; 15(10):1535-42. PubMed ID: 15367415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas.
    Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Ferreira VM; Lopes CS
    Hum Pathol; 2004 Jun; 35(6):663-9. PubMed ID: 15188131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
    Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas.
    Sundov D; Petric Mise B; Mrklic I; Bacic B; Vrdoljak E; Tomic S
    Neoplasma; 2017; 64(2):289-298. PubMed ID: 28052682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis.
    Dian D; Brüning A; Mylonas I
    Arch Gynecol Obstet; 2011 Aug; 284(2):437-43. PubMed ID: 20803206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of beta-catenin is associated with poor survival in ovarian carcinomas.
    Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS
    Int J Gynecol Pathol; 2004 Oct; 23(4):337-46. PubMed ID: 15381903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients.
    Hosono S; Kajiyama H; Terauchi M; Shibata K; Ino K; Nawa A; Kikkawa F
    Br J Cancer; 2007 Jan; 96(2):314-20. PubMed ID: 17211477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.
    Ho CM; Cheng WF; Lin MC; Chen TC; Huang SH; Liu FS; Chien CC; Yu MH; Wang TY; Hsieh CY
    Int J Gynecol Cancer; 2010 Dec; 20(9):1490-7. PubMed ID: 21119364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma.
    Shim HS; Yoon BS; Cho NH
    Hum Pathol; 2009 May; 40(5):693-8. PubMed ID: 19157508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases.
    Daraï E; Scoazec JY; Walker-Combrouze F; Mlika-Cabanne N; Feldmann G; Madelenat P; Potet F
    Hum Pathol; 1997 Aug; 28(8):922-8. PubMed ID: 9269828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
    Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
    Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type.
    Yamamoto S; Tsuda H; Honda K; Kita T; Takano M; Tamai S; Inazawa J; Yamada T; Matsubara O
    Mod Pathol; 2007 Dec; 20(12):1278-85. PubMed ID: 17873890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
    Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
    J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and localization of e-cadherin in epithelial ovarian cancer.
    Koensgen D; Freitag C; Klaman I; Dahl E; Mustea A; Chekerov R; Braicu I; Lichtenegger W; Sehouli J
    Anticancer Res; 2010 Jul; 30(7):2525-30. PubMed ID: 20682978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
    Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
    J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
    Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
    Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.